University of Toronto

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses.

Here are our picks for the top 10 news stories from MaRS Innovation’s portfolio.

Triphase-logo-Web1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study to evaluate marizomib in Glioblastoma (GBM) with Celgene, signed an agreement to provide Celgene with an option to acquire a new bi-specific antibody (licensed by Triphase from PharmAbcine) and closed the year by announcing that Triphase’s proteasome inhibitor, marizomib, demonstrates potent synergistic anti-multiple myeloma activity in combination with pomalidomide.

Flybits Corporate Logo2. Flybits Inc., spun out of Ryerson University, announced a $3.75 million Series A financing with Robert Bosch Venture Capital to advance its context-aware mobile experience platform. The company was also named a Red Herring Top 100 North America winner.

XLV Diagnostics Inc. 3. XLV Diagnostics Inc., spun out from Sunnybrook Health Sciences Centre and the Thunder Bay Regional Research Institute, secured a $3 million Series A investment round with Boston-based Bernard M. Gordon Unitrust. XLV’s product will provide mammography image quality equivalent to top-of-the-line mammography machines currently in use, and will do so at a fraction of the cost of current generation systems. The funding will support continued product development and regulatory approval.

Continue Reading

UTEST announces third cohort of U of T software start-ups

Products range from wearable digital coaches to socially-drive financial investment tools

utestTORONTO (Dec. 2, 2014) — The University of Toronto Early-Stage Technology (UTEST) incubator, co-directed by U of T’s Innovations & Partnerships Office (IPO) and MaRS Innovation, has announced its third cohort of computer science start-up companies.

Betakit and Electronic Products &Technology covered this announcement; TechVibes featured Syncadian and Onyx Motion in recent features. The U of T magazine also featured Syncadian and CEO Hanna Janossy in this recent profile.

The five companies and the diverse sectors they target are (scroll for full company descriptions):

  • FlatFab Inc. — 3D printing (designing 3D objects that print in 2D)
  • ICE3 Power Technologies Inc. — hardware (universal charger for portable devices)
  • Onyx Motion Inc. — wearables (digital coaching)
  • Nvest Inc. — financial investing (socially-driven stock recommendations)
  • Syncadian Inc. — digital health (fatigue management for enterprise clients)

Past graduates include Whirlscape, TrendMD, Crowdmark, eQOL and Granata Decision Systems, among others.

Continue Reading

UTEST gets a mention in TechVibes piece on Canada’s growing start-up scene

utestTechVibes gave UTEST, an incubator program jointly run by MaRS Innovation and the University of Toronto, a mention in Laura Leslie‘s “Canada’s Startup Communities Shining Brighter Than the California Sun,” published November 24, 2014, which explores the ecosystem-wide supports in place to encourage entrepreneurship in Canada.

Leslie writes:

Silicon Valley may be the first place that comes to mind when you think of tech startups, but when considering resources, financial support, and a welcoming atmosphere, Canada has been steadily putting itself on the map. The startup communities in cities such as Vancouver, Waterloo, Toronto, Calgary and Montreal have proven to be a sought after home for some of the world’s most notable tech  innovations of the last few years.

In a section on university supports, two of MaRS Innovation’s member institutions, the University of Toronto and Ryerson University, are cited for encouraging technology incubation and entrepreneurship: 

Continue Reading

Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease

Company’s collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug

Encycle IRICoR release
Encycle Therapeutics Inc., a biotechnology start-up founded by the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease.

TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease.

This announcement was covered in SciBX, Drug Discovery & Development, PBR, Yonge Street Media, Biotechnology Focus, and Bioworld Today (no public link available).

Read this release in French.

To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR), the Université de Montréal (UdeM) and MaRS Innovation. The partnership builds on the Merck Canada Inc. $4 million public-private funding partnership, announced at BIO in April 2013, to develop collaborative research projects with three Canadian academic commercialization centres, including MaRS Innovation and IRICoR.

“We are pleased to help support this important research collaboration that is made possible through the Quebec-Ontario corridor project in an emerging technology area. IRICoR, MaRS Innovation and Encycle have clearly leveraged their respective strengths to accelerate the discovery of novel therapeutics. As a research-focused company committed to early stage private-public partnering, we believe that such interactions will continue to fuel innovation in the life science sector in Canada,” said Mr. Chirfi Guindo, president and managing director, Merck Canada Inc.

The agreement brings a significant investment to fund Encycle Therapeutics’ development work, giving IRICoR an equity position and expanding MaRS Innovation’s equity stake. Cumulatively, Encycle Therapeutics has secured more than $2.5 million to advance its drug development platform.

Continue Reading

University of Toronto’s entrepreneurship programs to share over $3 million from province’s Campus-Linked Accelerator Program

UTEST among the four U of T entrepreneurship programs to be funded through Ontario’s CLA program

utestThe University of Toronto will receive $3,056,000 in funding over two years from the Ontario government to increase its training and support for student entrepreneurship.

The funding is part of the Campus-Linked Accelerator Program (CLA), announced today by Reza Moridi, Ontario’s Minister of Research and Innovation, and Minister of Training, Colleges and Universities.

“Fostering the entrepreneurial spirit among students is a key component of Ontario’s Youth Jobs Strategy, through programs that help transfer their ideas and skills to the marketplace while creating rewarding careers,” said Minister Moridi. “By partnering with colleges and universities to support entrepreneurship, we are ensuring our province’s business leaders of tomorrow are getting the support they need to succeed today.”

With this funding, U of T will continue to build on its long track record of success in this area by expanding the entrepreneurship opportunities it offers to students, primarily through its four principal accelerators: The Creative Destruction Lab (Rotman School of Management), The Hatchery (Faculty of Applied Science and Engineering), The Impact Centre (Faculty of Arts & Science), and UTEST (The Innovation and Partnerships Office, produced in partnership with MaRS Innovation).

The CLA program provides critical funding that enhances the support U of T and MaRS Innovation offer to our current UTEST companies,” said Kurtis Scissons, co-director of UTEST. “It also allows UTEST to expand to work with a greater number of student entrepreneurs in computer software, and is a catalyst for other UT CLA’s to combine their entrepreneurship efforts in a synergistic, complimentary way.”

Continue Reading

BioPrinter engineering team wins Canada Dyson Award

This story appears courtesy of our colleagues at U of T Engineering News.

The printer was developed by (clockwise from top right) University of Toronto students Arianna Mcallister and Lian Leng; former student Boyang Zhang and University of Toronto associate professor Axel Guenther. (Photo courtesy of the James Dyson Foundation)
The printer was developed by (clockwise from top right) University of Toronto students Arianna Mcallister and Lian Leng; former student Boyang Zhang and University of Toronto associate professor Axel Guenther. (Photo courtesy of the James Dyson Foundation)

While some of us are using the new power of 3D printers to make smartphone cases and chocolate figurines, two engineering students from the University of Toronto are using them to print functional human skin.

On September 18, Arianna McAllister and Lian Leng were named the Canadian winners of the 2014 James Dyson Award for their invention, the PrintAlive Bioprinter.

This story was covered by CBC News and BBC News. The BioPrinter team is working with MaRS Innovation to commercialize their technology; read the news archive.

This 3D skin printer won four U of T engineers a $3,500 Canada James Dyson Award and a chance to compete for a $60,000 international prize (photo courtesy of PrintAlive and U of T news).
This 3D skin printer won four U of T engineers a $3,500 Canada James Dyson Award and a chance to compete for a $60,000 international prize (photo courtesy of PrintAlive and U of T news).

The machine – created in collaboration with Professor Axel Guenther, alumnus Boyang Zhang and Dr. Marc Jeschke, head of Sunnybrook Hospital’s Ross Tilley Burn Centre – prints large, continuous layers of tissue that recreate natural skin.

Continue Reading

BioCentury features Encycle Therapeutics

Encycle Therapeutics

Encycle Therapeutics, a MaRS Innovation start-up company from the University of Toronto, was featured in a BioCentury emerging company profile by Michael J. Haas.

The company is currently raising a Series A financing round and employs eight people.

Haas’ profile, “Encycle: Oral Macrocycles,” is available behind a pay wall on the BioCentury website.

Here’s a short excerpt:

Macrocycle therapies can block protein-protein interactions that are undruggable with small molecules; however, oral availability and cell penetration remain key challenges. Encycle Therapeutics Inc.’s chemistry platform generates drug-like macrocycles against validated targets to treat diseases for which oral therapies are needed.

Marketed inhibitors of protein-protein interactions include biologics and other molecules large enough to target the wide, shallow surfaces involved in those interactions, but can only bind extracellular targets. Macrocycles can have sufficient size to block protein-protein interactions yet remain small enough to penetrate cells and block intracellular interactions that biologics and small molecules cannot.

Founded on chemistry from University of Toronto for cyclizing peptides and non-peptidic molecules, Encycle’s macrocycles incorporate three features that are not all found in other companies’ compounds — the absence of sulfur, the presence of intramolecular hydrogen bonding motifs, and an upper limit on size, according to President and CEO Jeffrey Coull.

Continue Reading

CBC’s Lang and O’Leary Exchange features Whirlscape’s Minuum keyboard

Whirlscape logoUTEST graduate Whirlscape, makers of the wearable, one-line Minuum keyboard, were recently featured on CBC’s Lang and O’Leary Exchange.

Minuum has also broken the 100 billion pixels mark in screen space saved for its users. Read about it on input, the Minuum blog.

Founder and CEO Will Walmsley was interviewed by Amanda Lang. The footage was also made available on CBC News, and was included in CBC’s weekly summary of the week’s top business stories. Watch the video.

Here’s an excerpt:

Typing on a smartphone is hard enough – imagine doing it on a smartwatch or other wearable device.

A Toronto startup called Minuum is trying to solve that problem with a tiny virtual keyboard.

It’s a downloadable app costing $3.99 that combines a tiny keyboard with a powerful autocorrect that helps you get the message out, no matter how you punch it.

[. . .]

“What really drives us to work on this technology is the future potential it has. The core concept is a keyboard that is just one line of characters, which means if you can imagine typing on a line anywhere, that can be a keyboard,” he said.

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top